Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
Founder & CEO of FLYR, Alex Mans, joins Cheddar to talk about the current state of the airline industry and how his company is updating technology in the sky.
Spirit Halloween CEO, Steve Silverstein, stops by Cheddar to talk SNL, this year's top costume ideas and why you should watch out for Spirit Christmas. Watch!
Brooks Running SVP of Footwear, Carson Caprara, introduces the new Glycerin Max and explains how leaning into innovation helps build customer brand loyalty
Ayako Yoshioka, Senior Portfolio Manager at Wealth Enhancement Group, discusses how data is indicating how the economy will fare in the fourth quarter of 2024.
